High Vista Strategies LLC Mirati Therapeutics, Inc. Transaction History

High Vista Strategies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $147,438 - $218,939	4,035 Added 34.48%	15,738 $585,000
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $36,812 - $87,969	892 Added 8.25%	11,703 $530,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $16,957 - $24,709	-285 Reduced 2.57%	10,811 $755,000
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $52,591 - $119,137	1,343 Added 13.77%	11,096 $745,000
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $39,198 - $78,051	517 Added 5.6%	9,753 $802,000

Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $98,611 - $142,146	747 Added 8.8%	9,236 $1.36 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $470,779 - $632,254	3,563 Added 72.33%	8,489 $1.5 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $95,040 - $118,621	660 Added 15.47%	4,926 $796,000
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $111,720 - $155,791	703 Added 19.73%	4,266 $731,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $26,414 - $39,164	163 Added 4.79%	3,563 $783,000
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $20,047 - $29,606	-177 Reduced 4.95%	3,400 $565,000
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $257,579 - $430,635	3,577 New	3,577 $408,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.